NEW YORK – Epigenetic markers can distinguish between individuals with type 2 diabetes who respond to metformin treatment and those who do not, a new study has found. Metformin is commonly prescribed to individuals with type 2 diabetes, but about 30 percent of patients don’t respond to the drug and between 20 percent and 30 percent experience side effects that can be intolerable.As part of the All New Diabetics In Scandia (ANDIS) study, researchers led by Lund University’s Charlotte Ling conducted a pharmacoepigenetic study to gauge whether epigenetic markers could be used to predict drug response and tolerance among type 2 diabetes patients (T2D).

Quelle: Epigenetic Markers Predict Type 2 Diabetes Patients Who Respond to, Tolerate Metformin | GenomeWeb